EI-1071

· Elixiron Immunotherapeutics (Hong Kong) Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for EI-1071, covering 2025-02-25 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients [Phase 2]

See pricing